EYPT Q1 2021 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-2.2% YoY

Gross Profit

$6M81.0% margin

Operating Income

-$11M-149.3% margin

Net Income

-$12M-167.7% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

+2.7%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$988,000

Balance Sheet

Total Assets

$187M

Total Liabilities

$71M

Stockholders' Equity

$116M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$7M	-2.2%
Gross Profit	$6M	$7M	-8.8%
Operating Income	-$11M	-$11M	+4.4%
Net Income	-$12M	-$13M	+6.8%

Revenue Segments

D E X Y C U Product

$4M55%

Y U T I Q Product

$3M45%